Pillstats
Rx only · Tablet, Extended Release · Oral

Bupropion

Bupropion Hydrochloride

3 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US5 NDCs
3 active makers
UKComing
soon
CAComing
soon
AUComing
soon
EUComing
soon
RxCUI (US)42347
US makers3 labelers
Packages19
DEA / ScheduleNone

US acquisition costNADAC · per unit

Average across 3 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.

$0.025$0.050$0.075$0.101Dec 2025Apr 2026Jul 2026
$0.078
Latest avg · Jul 22, 2026
-11%
Since Dec 17, 2025
3
Active US suppliers
84%
Top-2 supplier share*

Medicaid dispensing volumeSDUD · per quarter

Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.

2044096138182025 Q12025 Q22025 Q32025 Q42026 Q1
167
Rx · 2026 Q1
6.5K
Units dispensed
-77%
Rx vs. year ago
5
Quarters · since 2025 Q1

Who makes it3 active · 0 exited

US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.

LabelerTypePackagesStatus
Zydus Lifesciences Limitedunknown8SUPPLYING
Zydus Pharmaceuticals USA Inc.unknown8SUPPLYING
Proficient Rx LPunknown3SUPPLYING

Regulatory & supply eventsFDA · US

Shortages, recalls, and registration changes attached to this drug concept.

  • Nov 2, 2016
    RECALLRecall (Class III): BuPROPion Hydrochloride Extended-Release Tablets (XL), 300 mg, Rx Only, a) 30 count bottles (NDC 68382-354-06) and b)…

    Failed Dissolution Specifications; 6 month time point — Recalling firm: Zydus Pharmaceuticals USA Inc — Nationwide

  • Aug 3, 2016
    RECALLRecall (Class III): BuPROPion Hydrochloride Extended-Release Tablets, USP (XL) 300 mg, Rx Only, 500-count bottles, Manufactured by Cadila…

    Failed Dissolution Specifications: Product did not meet dissolution specification at an intermediate time point. — Recalling firm: Zydus Pharmaceuticals USA Inc — Nationwide